Jefferies Downgrades Option Care Health to Hold From Buy, Price Target is $32.05

Jefferies downgraded Option Care Health to 'Hold' from 'Buy' with a price target of $32.05. The stock has seen a 35.91% year-to-date increase but a 2.70% decline over the past 5 days. The downgrade is based on valuation, earnings revisions, and visibility metrics.

Original reporting
Published Oct 7, 2026, 11:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 12:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$OPCH
Bearish
medium confidence
Mentioned
$OPCH
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$OPCHBearishHigh
01

Why it matters

The downgrade could trigger a sell‑off, especially in pre‑market trading, and may influence peer valuations.

02

Market read

Analyst downgrade with a new target is a primary catalyst for short‑term price movement in OPCH.

03

What to watch

Potential upcoming contract wins or regulatory approvals that could offset the downgrade.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Option Care Health provides home infusion services; Jefferies' downgrade reflects concerns about earnings visibility.

Company-level read

Ticker impact

$OPCHBearishMedium confidence
Context

Jefferies downgraded Option Care Health to Hold and cut its price target to $32.05.

Expected impact

likely downward pressure as investors price in the lower target.

Evidence & confidence

Analyst downgrade with a reduced target is a fresh catalyst that typically prompts short-term selling.

Market effects

May weigh on other specialty health‑care stocks as analysts reassess sector outlook.

Limited to U.S. small‑cap health‑care segment.

Minimal global impact.

Counterpoint

If the downgrade reflects short‑term concerns, the stock could be undervalued relative to long‑term growth prospects.

Key entities

  • Option Care Health

    U.S. listed provider of home infusion services (ticker OPCH).

  • Jefferies

    Investment bank that issued the downgrade and new price target.

Related articles

$OPCHHighAI 9/10

Infusion therapy provider being acquired in $5.8 billion deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson in a $5.8 billion deal, expected to close in early 2027. CD&R will hold majority ownership, with McKesson holding a minority stake. Option Care Health shares were trading at $31.02, up from $23.34 before the acquisition news. The company will remain separate but will delist from Nasdaq post-deal.

$OPCHHighAI 9/10

Option Care stock surges on McKesson's home-infusion bet

Option Care Health (OPCH) shares rose 33% to $31.11 after McKesson (MCK) and Clayton, Dubilier & Rice agreed to take it private for $32.05 per share, valuing it at $5.8B. McKesson will initially own 49%, with an option to acquire the rest later. The deal gives McKesson access to Option Care's home-infusion network, serving 315K+ patients. Option Care's Q2 revenue grew 1.9% to $1.44B. The deal needs shareholder and regulatory approvals to close in early 2027.

$MCKHighAI 9/10

McKesson Plans $1.4 Billion Stake in $5.8 Billion Option Care Buyout

McKesson plans a $1.4B investment for a 49% stake in Option Care Health, part of a $5.8B buyout by Clayton, Dubilier & Rice. Shareholders will receive $32.05 per share. The deal, pending approvals, is expected to close in early 2027. Option Care shares rose 32.7% on the news. McKesson's Q1 revenue grew 8% to $105.4B, with net income down 22% to $614M.

$MCKHighAI 9/10

McKesson, private equity firm buy home infusion company, Option Care Health

McKesson Corporation and private equity firm Clayton Dubilier & Rice (CD&R) agreed to acquire Option Care Health, a home infusion company, for $5.8 billion. McKesson will invest $1.4 billion for a 49% stake, with CD&R taking 51%. The deal values Option Care Health at $32.05 per share, a 36% premium over Monday's closing price. Once completed, Option Care Health will become private and delist from Nasdaq.